<p>如果你有一些闲置现金，投资于一些支付股息的股票是个不错的主意。它们是被动收入的有用来源，可以帮助补充你的劳动收入。如果这种收入流随着时间的推移变得足够大，你可以依赖它来享受舒适的退休生活。</p>
<p>最佳的股息股票类型是那些在支付上有长期增长记录的公司。它们的业务应该具有强大的竞争壁垒、知名品牌，并且能够产生大量的自由现金流。这些特征提高了它们的股息在可预见的未来继续增长的可能性。</p>
<p>以下是三只高质量的股息股票，你应该投资。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTgwMjUvY29sYS1wb3VyaW5nLWludG8tZ2xhc3MuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTgwMjUvY29sYS1wb3VyaW5nLWludG8tZ2xhc3MuanBnJnc9NzAw"/></p>
<p>图片来源：Getty images。</p>
<h2>Sysco</h2>
<p><strong>Sysco</strong>（SYY -1.53%）向餐厅、医疗和教育机构以及娱乐场所等各种企业销售食品及相关产品。该公司是全球最大的食品分销商，在 10 个国家拥有 340 个分销中心。</p>
<p>多年来，它在收入和净利润方面都表现出稳定的增长，具体见下表。自由现金流在同一时期也相应增加。</p>
<table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>686.36 亿美元</td>
<td>763.25 亿美元</td>
<td>788.44 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>23.46 亿美元</td>
<td>30.39 亿美元</td>
<td>32.02 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>13.59 亿美元</td>
<td>17.7 亿美元</td>
<td>19.55 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>11.58 亿美元</td>
<td>20.75 亿美元</td>
<td>21.57 亿美元</td>
</tr>
</tbody>
</table>
<p>数据来源：Sysco。财政年度截至 6 月 30 日。</p>
<p>Sysco 报告了 2025 财政年度前九个月的业绩情况，结果喜忧参半。收入同比增长 3.3%，达到 602 亿美元，而由于运营和利息支出增加，净收入下降 3.4%，降至 13 亿美元。</p>
<p>尽管如此，该业务仍然产生了 7.85 亿美元的健康正自由现金流，尽管这比前一时期的 8.43 亿美元低了 7%。尽管如此，管理层将季度股息提高至 0.54 美元，比去年增长 6%，这也是连续第 56 年提高股息。</p>
<p>该公司有多个举措继续推动增长，这反过来应该有助于维持其股息增长的势头。其中一些包括个性化数字工具，以简化客户的采购流程，并提高其供应链的交付效率。</p>
<p>它特别指出其新的现金自取渠道是新客户的来源。这种模式提供比常规配送更低的价格，餐厅可以在每周七天内储备 “随时可用” 的产品。客户也更倾向于现金支付，以避免高额的信用卡费用，因此这为 Sysco 提供了一个可行的服务来源。</p>
<p>该公司目前仅占 17% 的市场份额，而其总可寻址市场（TAM）为 3700 亿美元，提供了充足的机会来增长其收入、股息和市场份额。该 TAM 从 2000 年的 1610 亿美元增长到目前的规模，显示出过去 25 年食品服务行业的稳定增长。</p>
<h2>强生</h2>
<p><strong>强生</strong>（JNJ -3.60%）是一家消费品和制药巨头，专注于创新药物和医疗技术。该公司有 26 种产品和平台年销售额超过 10 亿美元，其药物组合涵盖了广泛的疾病。</p>
<p>强生在过去三年中报告了收入和毛利润的增长，如下所示。由于 2023 年 8 月剥离了其 <strong>Kenvue</strong> 消费健康部门，净收入受到影响，因此表中显示的是其持续运营的净收入。在同一时期，自由现金流也持续增长。</p>
<table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>799.90 亿美元</td>
<td>851.59 亿美元</td>
<td>888.21 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>553.94 亿美元</td>
<td>586.06 亿美元</td>
<td>613.50 亿美元</td>
</tr>
<tr>
<td>净收入 *</td>
<td>163.70 亿美元</td>
<td>133.26 亿美元</td>
<td>140.66 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>171.85 亿美元</td>
<td>182.48 亿美元</td>
<td>198.42 亿美元</td>
</tr>
</tbody>
</table>
<p>数据来源：强生。财政年度截至 12 月 31 日。* 持续运营的净收入。</p>
<p>在 2025 年第一季度，销售额同比增长 2.4%，达到 219 亿美元。净收入（不包括一次性项目）几乎增长了 2%，达到 67 亿美元。该制药公司还产生了 47 亿美元的健康自由现金流，增长了 18.6%。其强大的品牌和持续的自由现金流生成使公司能够宣布其连续第 63 年增加年度股息，季度支付从每股 1.24 美元上升至 1.30 美元，增长 4.8%。</p>
<p>投资者可以期待根据公司对 2025 年的积极指引看到更多增长。销售预计在中点上同比增长 2.5%，而调整后的每股收益预计同比增长 6.2%。</p>
<p>管理层还特别指出，预计到 2027 年和 2028 年将产生十亿美元销售的创新药物。分析师预计用于治疗耐药性抑郁症的鼻用喷雾剂 Spravato 的销售额将在 21 亿到 23 亿美元之间，但公司内部估计这一数字将高出 50%。</p>
<p>用于治疗重度克罗恩病的 Tremfya，分析师预测销售额将在 57 亿到 63 亿美元之间，但强生认为这一数字将高出 25%。该公司还有两种药物在研发中，预计到 2028 年将成为十亿美元产品。</p>
<p>这些估计应该能给投资者信心，认为强生能够在未来几年继续增长其收入、收益和股息。</p>
<h2>可口可乐</h2>
<p><strong>可口可乐</strong>(KO -0.76%) 在全球销售约 200 种饮料品牌，每天提供 22 亿瓶饮料。其产品组合包括其标志性的软饮料、Dasani 矿泉水和 Minute Maid 果汁。</p>
<p>可口可乐多年来成功地稳步增长其收入和净利润，如下表所示。自由现金流在这些年中也一直保持正值，但由于更高的营运资本需求，2024 年受到了一定影响。</p>
<table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>430.04 亿美元</td>
<td>457.54 亿美元</td>
<td>470.61 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>109.09 亿美元</td>
<td>113.11 亿美元</td>
<td>99.92 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>95.42 亿美元</td>
<td>107.14 亿美元</td>
<td>106.31 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>95.34 亿美元</td>
<td>97.47 亿美元</td>
<td>47.41 亿美元</td>
</tr>
</tbody>
</table>
<p>数据来源：可口可乐。财政年度截至 12 月 31 日。</p>
<p>2025 年第一季度的结果喜忧参半，收入同比下降 2%，降至 111 亿美元。然而，净收入增长了 5%，达到了 33 亿美元。今年早些时候，董事会批准了第 63 次连续年度股息增加，将年度股息提高至每股 2.04 美元，较前一年的 1.94 美元有所上升。</p>
<p>对于 2025 年，投资者可以期待公司实现 5% 至 6% 的有机收入增长，以及每股收益增长约 2% 至 3%。预计自由现金流约为 95 亿美元。管理层认为，进一步增长的机会巨大，因为发达市场仅占全球人口的 20%，剩余的 80% 仍然可以作为目标市场。</p>
<p>在这些发展中或新兴市场中，几乎 70% 的人口不消费任何商业饮料，这为可口可乐提供了一个诱人的机会，以扩大其市场份额和影响力。</p>

强生

<p>本文讨论了投资于支付股息股票以获取被动收入和退休的好处。文章强调了 Sysco，这是一家全球最大的食品分销商，拥有强劲的增长轨迹和 56 年的持续增息历史。强生公司也被提及，以其创新的医疗产品和稳定的股息增长而闻名。这两家公司展现了稳健的财务表现和增长潜力，使其成为希望投资 5000 美元于股息股票的投资者的吸引选项</p>

<p>If you have some spare cash, it's a great idea to put it into some dividend-paying stocks. They're a useful source of passive income that can help supplement your earned income. And if this income stream becomes large enough over time, you can rely on it to enjoy a comfortable retirement.</p>
<div class="lb-trans"><p>如果你有一些闲置现金，投资于一些支付股息的股票是个不错的主意。它们是被动收入的有用来源，可以帮助补充你的劳动收入。如果这种收入流随着时间的推移变得足够大，你可以依赖它来享受舒适的退休生活。</p>
</div><p>The best types of dividend stocks are companies that have demonstrated a long track record of rising payouts. Their businesses should have a strong competitive moat, recognizable brands, and generate copious amounts of free cash flow. These attributes create a higher probability that their dividends can continue to increase for the foreseeable future.</p>
<div class="lb-trans"><p>最佳的股息股票类型是那些在支付上有长期增长记录的公司。它们的业务应该具有强大的竞争壁垒、知名品牌，并且能够产生大量的自由现金流。这些特征提高了它们的股息在可预见的未来继续增长的可能性。</p>
</div><p>Here are three high-quality dividend stocks that you should spend your money on.</p>
<div class="lb-trans"><p>以下是三只高质量的股息股票，你应该投资。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTgwMjUvY29sYS1wb3VyaW5nLWludG8tZ2xhc3MuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F818025%2Fcola-pouring-into-glass.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty images.</p>
<div class="lb-trans"><p>图片来源：Getty images。</p>
</div><h2>Sysco</h2>
<div class="lb-trans"><h2>Sysco</h2>
</div><p><strong>Sysco</strong>(SYY -1.53%) sells food and related products to a wide range of businesses such as restaurants, healthcare and education facilities, and entertainment venues. The company is the world's largest food distributor, with 340 distribution centers across 10 countries.</p>
<div class="lb-trans"><p><strong>Sysco</strong>（SYY -1.53%）向餐厅、医疗和教育机构以及娱乐场所等各种企业销售食品及相关产品。该公司是全球最大的食品分销商，在 10 个国家拥有 340 个分销中心。</p>
</div><p>It has demonstrated steady growth in both its top and bottom lines over the years, as shown in the table below. Free cash flow has also correspondingly increased over the same period.</p>
<div class="lb-trans"><p>多年来，它在收入和净利润方面都表现出稳定的增长，具体见下表。自由现金流在同一时期也相应增加。</p>
</div><table>
<thead>
<tr>
<th>Metric</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$68.636 billion</td>
<td>$76.325 billion</td>
<td>$78.844 billion</td>
</tr>
<tr>
<td>Operating income</td>
<td>$2.346 billion</td>
<td>$3.039 billion</td>
<td>$3.202 billion</td>
</tr>
<tr>
<td>Net income</td>
<td>$1.359 billion</td>
<td>$1.77 billion</td>
<td>$1.955 billion</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>$1.158 billion</td>
<td>$2.075 billion</td>
<td>$2.157 billion</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>686.36 亿美元</td>
<td>763.25 亿美元</td>
<td>788.44 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>23.46 亿美元</td>
<td>30.39 亿美元</td>
<td>32.02 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>13.59 亿美元</td>
<td>17.7 亿美元</td>
<td>19.55 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>11.58 亿美元</td>
<td>20.75 亿美元</td>
<td>21.57 亿美元</td>
</tr>
</tbody>
</table>
</div><p>Data source: Sysco. Fiscal years end June 30.</p>
<div class="lb-trans"><p>数据来源：Sysco。财政年度截至 6 月 30 日。</p>
</div><p>Sysco reported a mixed set of earnings for the first nine months of fiscal 2025. Revenue inched up 3.3% year over year to $60.2 billion, while net income fell by 3.4% to $1.3 billion because of higher operating and interest expenses.</p>
<div class="lb-trans"><p>Sysco 报告了 2025 财政年度前九个月的业绩情况，结果喜忧参半。收入同比增长 3.3%，达到 602 亿美元，而由于运营和利息支出增加，净收入下降 3.4%，降至 13 亿美元。</p>
</div><p>The business continued to generate a healthy positive free cash flow at $785 million, though this was 7% below the $843 million in the previous period. Nevertheless, management raised its quarterly dividend to $0.54, 6% higher than the previous year, making this the 56th consecutive year of rising dividends.</p>
<div class="lb-trans"><p>尽管如此，该业务仍然产生了 7.85 亿美元的健康正自由现金流，尽管这比前一时期的 8.43 亿美元低了 7%。尽管如此，管理层将季度股息提高至 0.54 美元，比去年增长 6%，这也是连续第 56 年提高股息。</p>
</div><p>The company has multiple initiatives to continue driving growth, which in turn should help it to maintain its dividend streak. Some of these include personalized digital tools to ease customers' purchasing, and to make its supply chain more efficient in delivery.</p>
<div class="lb-trans"><p>该公司有多个举措继续推动增长，这反过来应该有助于维持其股息增长的势头。其中一些包括个性化数字工具，以简化客户的采购流程，并提高其供应链的交付效率。</p>
</div><p>It singled out its new cash-and-carry channel as a source of new customers. This format offers lower prices than regular delivery, with restaurants stocking up on &#34;ready now&#34; products seven days a week. Customers also prefer to pay in cash to avoid expensive credit card fees, thus making this a viable source for Sysco to serve.</p>
<div class="lb-trans"><p>它特别指出其新的现金自取渠道是新客户的来源。这种模式提供比常规配送更低的价格，餐厅可以在每周七天内储备 “随时可用” 的产品。客户也更倾向于现金支付，以避免高额的信用卡费用，因此这为 Sysco 提供了一个可行的服务来源。</p>
</div><p>The company currently has just a 17% market share with a total addressable market (TAM) of $370 billion, offering ample opportunity to grow its revenue, dividends, and market share. This TAM has more than doubled from just $161 billion in 2000 to its current size, showing the steady growth of the food-service industry over the past 25 years.</p>
<div class="lb-trans"><p>该公司目前仅占 17% 的市场份额，而其总可寻址市场（TAM）为 3700 亿美元，提供了充足的机会来增长其收入、股息和市场份额。该 TAM 从 2000 年的 1610 亿美元增长到目前的规模，显示出过去 25 年食品服务行业的稳定增长。</p>
</div><h2>Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>强生</h2>
</div><p><strong>Johnson &amp; Johnson</strong>(JNJ -3.60%) is a consumer goods and pharmaceutical giant that specializes in innovative medicine and medical technology. The company has 26 products and platforms that generate more than $1 billion in annual sales, and its portfolio of medicines addresses a wide range of diseases.</p>
<div class="lb-trans"><p><strong>强生</strong>（JNJ -3.60%）是一家消费品和制药巨头，专注于创新药物和医疗技术。该公司有 26 种产品和平台年销售额超过 10 亿美元，其药物组合涵盖了广泛的疾病。</p>
</div><p>Johnson &amp; Johnson reported growing revenue and gross profit over the last three years, as shown below. Net income was affected by the divestment of its <strong>Kenvue</strong> consumer health division in August 2023, and so the table shows net income from its continuing operations. Free cash flow has also kept marching higher over the same period.</p>
<div class="lb-trans"><p>强生在过去三年中报告了收入和毛利润的增长，如下所示。由于 2023 年 8 月剥离了其 <strong>Kenvue</strong> 消费健康部门，净收入受到影响，因此表中显示的是其持续运营的净收入。在同一时期，自由现金流也持续增长。</p>
</div><table>
<thead>
<tr>
<th>Metric</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$79.990 billion</td>
<td>$85.159 billion</td>
<td>$88.821 billion</td>
</tr>
<tr>
<td>Operating income</td>
<td>$55.394 billion</td>
<td>$58.606 billion</td>
<td>$61.350 billion</td>
</tr>
<tr>
<td>Net income*</td>
<td>$16.370 billion</td>
<td>$13.326 billion</td>
<td>$14.066 billion</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>$17.185 billion</td>
<td>$18.248 billion</td>
<td>$19.842 billion</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>799.90 亿美元</td>
<td>851.59 亿美元</td>
<td>888.21 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>553.94 亿美元</td>
<td>586.06 亿美元</td>
<td>613.50 亿美元</td>
</tr>
<tr>
<td>净收入 *</td>
<td>163.70 亿美元</td>
<td>133.26 亿美元</td>
<td>140.66 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>171.85 亿美元</td>
<td>182.48 亿美元</td>
<td>198.42 亿美元</td>
</tr>
</tbody>
</table>
</div><p>Data source: Johnson &amp; Johnson. Fiscal years end Dec. 31. *Net income from continuing operations.</p>
<div class="lb-trans"><p>数据来源：强生。财政年度截至 12 月 31 日。* 持续运营的净收入。</p>
</div><p>For the first quarter of 2025, sales increased 2.4% year over year to $21.9 billion. Net income (excluding one-off items) inched up almost 2% to $6.7 billion. The pharmaceutical company also generated a healthy free cash flow of $4.7 billion, up 18.6%. Its strong franchise and consistent free cash flow generation enabled the company to declare its 63rd consecutive annual dividend increase, with its quarterly payout rising 4.8% year over year from $1.24 to $1.30 per share.</p>
<div class="lb-trans"><p>在 2025 年第一季度，销售额同比增长 2.4%，达到 219 亿美元。净收入（不包括一次性项目）几乎增长了 2%，达到 67 亿美元。该制药公司还产生了 47 亿美元的健康自由现金流，增长了 18.6%。其强大的品牌和持续的自由现金流生成使公司能够宣布其连续第 63 年增加年度股息，季度支付从每股 1.24 美元上升至 1.30 美元，增长 4.8%。</p>
</div><p>Investors can expect to see more growth based on the company's encouraging guidance for 2025. Sales are expected to increase by 2.5% year over year at the midpoint, while adjusted earnings per share are projected to rise by 6.2% year over year.</p>
<div class="lb-trans"><p>投资者可以期待根据公司对 2025 年的积极指引看到更多增长。销售预计在中点上同比增长 2.5%，而调整后的每股收益预计同比增长 6.2%。</p>
</div><p>Management also singled out innovative medicines that are expected to generate billion-dollar sales by 2027 and 2028. Analysts expect Spravato, a nasal spray for adults with treatment-resistant depression, to garner $2.1 billion to $2.3 billion of sales, but internal company estimates put this at 50% higher.</p>
<div class="lb-trans"><p>管理层还特别指出，预计到 2027 年和 2028 年将产生十亿美元销售的创新药物。分析师预计用于治疗耐药性抑郁症的鼻用喷雾剂 Spravato 的销售额将在 21 亿到 23 亿美元之间，但公司内部估计这一数字将高出 50%。</p>
</div><p>Tremfya, for adults with severe Crohn's disease, has analysts predicting sales of between $5.7 billion to $6.3 billion, but Johnson &amp; Johnson believes that will be 25% higher. The company also has two more drugs in its pipeline that it projects will become billion-dollar products by 2028.</p>
<div class="lb-trans"><p>用于治疗重度克罗恩病的 Tremfya，分析师预测销售额将在 57 亿到 63 亿美元之间，但强生认为这一数字将高出 25%。该公司还有两种药物在研发中，预计到 2028 年将成为十亿美元产品。</p>
</div><p>These estimates should provide investors with the confidence that Johnson &amp; Johnson can continue to grow its revenue, earnings, and dividends in the years ahead.</p>
<div class="lb-trans"><p>这些估计应该能给投资者信心，认为强生能够在未来几年继续增长其收入、收益和股息。</p>
</div><h2>Coca-Cola</h2>
<div class="lb-trans"><h2>可口可乐</h2>
</div><p><strong>Coca-Cola</strong>(KO -0.76%) sells around 200 beverage brands worldwide, delivering 2.2 billion drinks daily. Its portfolio includes its namesake soft drink, along with Dasani mineral water and Minute Maid fruit juices.</p>
<div class="lb-trans"><p><strong>可口可乐</strong>(KO -0.76%) 在全球销售约 200 种饮料品牌，每天提供 22 亿瓶饮料。其产品组合包括其标志性的软饮料、Dasani 矿泉水和 Minute Maid 果汁。</p>
</div><p>Coca-Cola has managed to grow its revenue and net income steadily over the years, as shown in the table below. Free cash flow has also been positive all these years, but took a hit in 2024 because of higher working-capital requirements.</p>
<div class="lb-trans"><p>可口可乐多年来成功地稳步增长其收入和净利润，如下表所示。自由现金流在这些年中也一直保持正值，但由于更高的营运资本需求，2024 年受到了一定影响。</p>
</div><table>
<thead>
<tr>
<th>Metric</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$43.004 billion</td>
<td>$45.754 billion</td>
<td>$47.061 billion</td>
</tr>
<tr>
<td>Operating income</td>
<td>$10.909 billion</td>
<td>$11.311 billion</td>
<td>$9.992 billion</td>
</tr>
<tr>
<td>Net income</td>
<td>$9.542 billion</td>
<td>$10.714 billion</td>
<td>$10.631 billion</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>$9.534 billion</td>
<td>$9.747 billion</td>
<td>$4.741 billion</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>430.04 亿美元</td>
<td>457.54 亿美元</td>
<td>470.61 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>109.09 亿美元</td>
<td>113.11 亿美元</td>
<td>99.92 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>95.42 亿美元</td>
<td>107.14 亿美元</td>
<td>106.31 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>95.34 亿美元</td>
<td>97.47 亿美元</td>
<td>47.41 亿美元</td>
</tr>
</tbody>
</table>
</div><p>Data source: Coca-Cola. Fiscal years end Dec. 31.</p>
<div class="lb-trans"><p>数据来源：可口可乐。财政年度截至 12 月 31 日。</p>
</div><p>The first quarter of 2025 saw mixed results, with revenue dipping by 2% year over year to $11.1 billion. Net income, however, rose 5% to $3.3 billion. Earlier this year, the board of directors approved its 63rd consecutive annual dividend increase, bringing its annual dividend to $2.04 per share, up from $1.94 in the prior year.</p>
<div class="lb-trans"><p>2025 年第一季度的结果喜忧参半，收入同比下降 2%，降至 111 亿美元。然而，净收入增长了 5%，达到了 33 亿美元。今年早些时候，董事会批准了第 63 次连续年度股息增加，将年度股息提高至每股 2.04 美元，较前一年的 1.94 美元有所上升。</p>
</div><p>For 2025, investors can expect the company to deliver organic revenue growth of between 5% to 6% along with earnings-per-share growth of around 2% to 3%. About $9.5 billion of free cash flow is expected. Management sees vast opportunities for further growth as developed markets only account for 20% of the global population, leaving the remaining 80% open for it to target.</p>
<div class="lb-trans"><p>对于 2025 年，投资者可以期待公司实现 5% 至 6% 的有机收入增长，以及每股收益增长约 2% 至 3%。预计自由现金流约为 95 亿美元。管理层认为，进一步增长的机会巨大，因为发达市场仅占全球人口的 20%，剩余的 80% 仍然可以作为目标市场。</p>
</div><p>In these developing or emerging markets, almost 70% of the population does not consumer any commercial beverages, offering Coca-Cola a tantalizing opportunity to expand its presence and market share.</p>
<div class="lb-trans"><p>在这些发展中或新兴市场中，几乎 70% 的人口不消费任何商业饮料，这为可口可乐提供了一个诱人的机会，以扩大其市场份额和影响力。</p>
</div>

目前用 5000 美元购买的最具智慧的股息股票